Novo Nordisk (0QIU) Gets a Buy from Goldman Sachs
Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00.
‘We made 434pc on one stock – now we’re hunting for the next Ozempic’
Fund Of The Week quizzes fund managers about how they’re investing your money. If you’d like to suggest which funds you want ...
Will Natco and Dr. Reddy’s bet on weight-loss drug Ozempic’s copy pay off?
In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.
Novo Nordisk call volume above normal and directionally bullish
Bullish option flow detected in Novo Nordisk (NVO) with 21,940 calls trading, 1.5x expected, and implied vol increasing almost 3 points to ...
24/7 Wall St18h
VEA vs VWO: Which International Vanguard ETF Is Worth Owning?
There are many opportunities available in the international markets that never make the news in the US. The VEA and VWO ETFs ...
Man, 52, ‘cured’ of his 15-year cocaine habit after taking weight loss jab in first case of its kind
A 52-year-old man has knocked his decade-long cocaine addiction on the head after receiving weight-loss injections. The jab ...
Zacks Small Cap Research on MSN20h
RANI: Impressive Bioavailability for RT-116
RANI READ THE FULL RANI RESEARCH REPORT On February 5th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...
Employer-Sponsored GLP-1 Coverage Becomes Critical for Talent Retention and Acquisition, New 9amHealth Survey Finds
As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...
MarketBeat on MSN22h
These 3 Stocks Just Announced Major Dividend Hikes
These three stocks just announced significant quarterly dividend increases that they are set to pay out soon. While they all ...